Oncology - Supporting earlier diagnosis of multiple myeloma with serum free light chain assays
View as a Web Page
News Medical
 
  Oncology Oncology logo  
  The latest oncology news from News Medical  
 

Event guide: World ADC San DiegoEvent guide: World ADC San Diego

For the most comprehensive insights into the World ADC San Diego conference, download the official event guide. Packed with detailed agendas, speaker lineups, and key discussion topics, this guide is your essential resource to navigate the world’s longest-standing and most definitive ADC forum.

Download the eBook
 
 
    Supporting earlier diagnosis of multiple myeloma with serum free light chain assaysSupporting earlier diagnosis of multiple myeloma with serum free light chain assays
 
Multiple myeloma (MM) is the second most common hematological malignancy in the United Kingdom (UK), claiming approximately 3000 lives each year, corresponding to at least two percent of all cancer-related deaths. This article examines the current challenges in diagnosing MM, and how advances in diagnostic technologies could help patients suffering from this disease.
 
Read the full article today
 
 
   AI-designed proteins bring personalized cancer treatment within reachAI-designed proteins bring personalized cancer treatment within reach
 
Precision cancer treatment on a larger scale is moving closer after researchers have developed an AI platform that can tailor protein components and arm the patient's immune cells to fight cancer.
 
 Researchers pinpoint PRMT5 as a promising target for cancer drugs
 
Researchers pinpoint PRMT5 as a promising target for cancer drugsA potential target for experimental drugs that block PRMT5 - a naturally occurring enzyme some tumors rely more on for survival - has been identified by researchers with the Fralin Biomedical Research Institute's Cancer Research Center in Washington, D.C.
 
 
 Salk researcher awarded funding to boost immunotherapy for pancreatic cancer
 
Salk researcher awarded funding to boost immunotherapy for pancreatic cancerSalk Institute Professor Diana Hargreaves was named a 2025 All-Star Translational Award Program grantee by the V Foundation for Cancer Research.
 
 
 Different anti-PD-L1 antibodies show varied results in tumor growth inhibition
 
Different anti-PD-L1 antibodies show varied results in tumor growth inhibitionImmune checkpoint inhibitors (ICIs), a powerful form of immunotherapy, have revolutionized cancer treatment by unleashing the body's own immune system to fight tumors.
 
 
 Restoring mitochondria enhances immune response against lung cancer
 
Restoring mitochondria enhances immune response against lung cancerWhile chemotherapy remains a cornerstone of lung cancer treatment, it often weakens the immune system it relies on for long-term control.
 
 
 AI algorithm identifies one-third of missed breast cancers in DBT screenings
 
AI algorithm identifies one-third of missed breast cancers in DBT screeningsAn AI algorithm for breast cancer screening has potential to enhance the performance of digital breast tomosynthesis (DBT), reducing interval cancers by up to one-third, according to a study published today in Radiology, a journal of the Radiological Society of North America.
 
 
 Advanced Genetic Analysis with the epicGEN Solid Cancer and MSI Kit
 
Advanced Genetic Analysis with the epicGEN Solid Cancer and MSI KitHighly sensitive and efficient analysis with an emphasis on specific regions of the genome. epicGEN NGS panels are designed for modern diagnostic laboratories.
 
 

How would you rate today's newsletter?

 
             
 
 
Google News Icon Stay updated with the latest in health and medical news! Follow News‑Medical.net on Google News for real‑time updates. Click here to follow us now.
 
Facebook X Instagram LinkedIn Vimeo
Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of our websites and requested to be notified of additional information.

Unsubscribe or Update Notification Preferences

Contact | About | Privacy Policy

- - - - - -

Registered Address:
AZoNetwork UK Ltd., NEO, 9 Charlotte St, Manchester, M1 4ET, UK

Manchester | Sydney | Boston

Copyright © 2000-2025